胰岛素样生长因子1作为渐进性中部早期青春期的诊断标志物:一项前性研究
Ana Luísa Leite1,2,3,4, Luís Filipe Azevedo5,6, Rosa Arménia Campos7,8
1Unit of Paediatric Endocrinology and Diabetes, Department of Paediatrics, Unidade Local de Saúde Gaia e Espinho, Vila Nova de Gaia, Portugal. ana.leite@ulsge.min-saude.pt.
European journal of pediatrics
|June 24, 2025
概括
胰岛素类生长因子1 (IGF-1) 和其标准偏差得分 (SDS) 可以可靠地预测女孩的中央早熟青春期 (CPP). 升高的IGF-1 SDS水平可能有助于避免对早期青春期症状进行侵入性测试.
科学领域:
- 儿科内分泌学 儿科内分泌学
- 生殖医学 生殖医学
- 生物标志物发现发现
背景情况:
- 中央早熟性青春期 (CPP) 诊断通常涉及侵入性淋巴激素释放激素 (GnRH) 刺激测试.
- 胰岛素类生长因子1 (IGF-1) 水平在青春期自然增加,是生长和青春期进展的指标.
研究的目的:
- 评估IGF-1和IGF-1标准偏差分数 (SDS) 的可靠性,以预测女孩的渐进性CPP.
- 探索非侵入性IGF-1测量在诊断CPP和减少侵入性测试的需要方面的潜力.
主要方法:
- 一项前性研究涉及82名8岁以下的女孩,分为CPP,非进展性CPP (NP-CPP) 与过渡性 (IT) 组,以及对照组.
- 测量包括人体测量,坦纳分期,骨年龄,骨盆超声波和血清IGF-1和IGF-1SDS水平.
- 用GnRH刺激测试来确认CPP的诊断.
主要成果:
- 与NP-CPP和对照组相比,CPP组的平均IGF-1和IGF-1SDS水平明显高于NP-CPP和对照组 (p < 0.001).
- 多变量逻辑回归确定IGF-1 (OR=1.025) 和IGF-1 SDS (OR=8.721) 作为CPP的显著预测因素.
- 对IGF-1 (AUC=0.837) 和IGF-1 SDS (AUC=0.862) 的ROC分析显示了高准确度,特定的切断值显示出良好的灵敏度和特异性.
结论:
- IGF-1和IGF-1 SDS是有效的非侵入性标志物,用于区分CPP和非进展性早熟青春期.
- 1.44的IGF-1 SDS切断值显示出高特异性和诊断准确性,可能避免了侵入性GnRH刺激测试的需要.
- 这些发现支持将IGF-1测量纳入早期青春期迹象的女孩的初始诊断工作.
相关概念视频
Signs of Puberty
644
Puberty is a critical phase, typically beginning between the ages of 8 and 13 in girls and 9 and 14 in boys, though timing can vary based on genetics, environmental factors, and overall health. This period is characterized by the development of secondary sexual characteristics and the attainment of reproductive potential. Endocrine changes underpin puberty, with hormonal surges of Luteinizing Hormone (LH) and Follicle-Stimulating Hormone (FSH) instigated by Gonadotropin-Releasing Hormone (GnRH)...
644
Insulin: Dosing Regimen and Adverse Effects
270
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
270


